Highlights from Day 1 of ESMO Asia 2024

ESMO Asia is an annual congress focused on multidisciplinary oncology in the Asian region. ESMO Asia 2024 is being held from 6-8 December, at Singapore.

It provides a platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field.The event brings together oncologists, researchers, healthcare professionals, and industry representatives from Asia and around the world.

ESMO Asia 2024 features scientific sessions covering a wide range of topics related to oncology, including advances in cancer research, new treatment modalities, and discussions on the management of specific types of cancer. Its educational sessions provide in-depth training and insights into specific aspects of oncology, ensuring that participants gain practical knowledge that they can apply in their daily practice.

For More Information About the ESMO Asia 2024, Visit Here.

Healthcare Professionals and Organizations shared about this Conference on Social Media:

ESMO

“ESMO Asia24: Early results from a phase IIIb TOURMALINE trial support 30-minute infusions of immunotherapy with some advantages for patients with advanced Biliary Tract Cancer.”

Herbert Loong

“Thrilled to meet these lovely individuals who keep the YOC of ESMO fun, active, informative and energetic at ESMO Asia 2024.”

Tom Powles

“While EVP is better than platinum based chemotherapy in advanced bladder cancer, the debate whether cisplatin is much better than carbo goes on. Here we show cisplatin combines a bit better with pembro than carbo. Matt Galsky maybe winning ESMO Asia 2024.”

Sophia Wong

“What an honour hosting Haanen John today – talking all cell therapy, TIL therapy and visiting our national GMP facility  

And a fascinating talk on myeloids in lung with Charles Swanton.”

Antonio Giordano

“Kick off for the largest oncology conference in Asia with over 4,000 participants ESMO Asia 2024.”

Liz Connolly

“Lots of super sessions for Young Oncologists this year at ESMO Asia24, Great opportunity to meet & talk with some amazing international experts.

Any YOs here, please make sure to check them out or drop by and say hello.”

Melissa Eastgate

“Very honoured to be representing Medical Oncology Group of Australia at ESMO Asia24. One of our own Georgina Longdoing a fantastic job as the Scientific co-chair.”

Laird Cameron

“ESMO Asia24 Thank you to Dr Yamamoto for presenting exciting data on Zongertinib tailored for our Her2 NSCLC patients.”

Jordi Remon

“Future of ADCs in NSCLC looks more promising for EGFRm NSCLC Pooled analysis TROPION Lung01 and 05 evaluating datopotamab deruxtecan in EGFRm. Activity promising, but ~ to platinum/Pemetrexed.

Future?
Osi -> Chemo -> Dato?
Osi + Ct -> Dato?
Lazer + Ami ->CT->Dato?”

Roberto Iacovelli

“Let’s start with ESMO ASIA24. Interesting and interactive discussion about oligometastatic RCC with some friends and colleagues from Asia and Europe. Thanks to Darren Poon and Marniza.”

Lorenza Rimassa

“Jin Won Kim presents Asia subgroup OS and long-term follow-up results of the HERIZON-BTC-01 study of zanidatamab in HER2 positive BTC at ESMO Asia 2024.”

Angela Lamarca

“Update form HERIZON-BTC-01 trial in HER2 +ve Biliary Cancer – Asian population with Zanidatamab Higher rate of HER-2 2+ included (28% vs 13% in general population)  

Similar ORR 42%.
Safety.”

Antonio Giordano

“New way to target cell cycle. Cyclin through Innovation. ESMO ASIA24 with Drs. Lee and Naito. Exciting new drugs to target CDK4, CDK2, and more in HR+/Her2- MBC. Taking 2L PFS closer to 12 months and away from chemo.”

Enrique Grande

“Great session Syed Hussain!!!! My only concern was about the moderator Ravindran Kanesvaran. Do you think he felt asleep during Ben Tran talk?  

Amazing ESMO Asia24 Fantastic discussion about Bladder Cancer.”

Angela Lamarca

“Combined Tissue and ctDNA NGS in solid tumours combined NGS detects more targetable alterations ctDNA is quick and can change practice even more than tissue.”

Matteo Lambertini

“My last session as part of the ESMO YOC…a great privilege to serve ESMO in the past years together with the best team ever…really really grateful to you all.”

Icro Meattini

“Great time ESMO Asia24 talking about oligometastatic status and multimodal treatment options for Breast Cancer at the ESMO discussion Hub Honoured to be introduced by a great friend Kevin Punie.”

ESMO

“ESMO Asia24: Agents targeting B7-H3 and CEACAM6 pass their initial clinical tests, according to results from first-in-human trials.”